Publications

Found 6 results
Author Title [ Type(Desc)] Year
Filters: Keyword is Dependovirus  [Clear All Filters]
Journal Article
Rosenberg JB, Kaplitt MG, De BP, Chen A, Flagiello T, Salami C, Pey E, Zhao L, Arbona RJRicart, Monette S et al..  2018.  AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease.. Hum Gene Ther Clin Dev. 29(1):24-47.
Niethammer M, Tang CC, Vo A, Nguyen N, Spetsieris P, Dhawan V, Ma Y, Small M, Feigin A, During MJ et al..  2018.  Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity.. Sci Transl Med. 10(469)
During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P, Xiao X, Li J, Freese A, Taylor JR, Roth RH et al..  1998.  In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector.. Gene Ther. 5(6):820-7.
Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S, Vernov M, Stavarache M, Musatov S, Flajolet M et al..  2010.  Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med. 2(54):54ra76.
Stavarache MA, Petersen N, Jurgens EM, Milstein ER, Rosenfeld ZB, Ballon DJ, Kaplitt MG.  2018.  Safe and stable noninvasive focal gene delivery to the mammalian brain following focused ultrasound. J Neurosurg. 130(3):989-998.
Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D et al..  2007.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 369(9579):2097-105.